



ATLAS

ASIAN CLINICAL TRIALS NETWORK FOR CANCERS PROJECT

ANNUAL REPORT

2025

Table of Contents

- Messages from the ATLAS Board President and NCCH Director
- About the ATLAS Project
- 2025 Highlights
- Clinical Research
- ATLAS Governance
- Education
- Activity Report

The names and designations used in this report are for descriptive and operational purposes only and do not imply any position on legal status, sovereignty, or diplomatic recognition.



Darren Lim, MD. PhD.

National Cancer Centre Singapore

ATLAS Board President

As President of the ATLAS Board, I am honored to share this Annual Report with our members and partners. ATLAS is an investigator driven network that connects institutions across Asia to deliver clinical studies relevant to the region while meeting global standards. Over the past year, we have strengthened collaboration through our study groups, governance activities, and capacity building programs. The next step is to translate this platform into more impactful investigator initiated trials and to deepen engagement with regulators, industry, and patient communities. I thank the ATLAS HQ team, the Asian Partnerships Office, and every participating institution for their sustained commitment. Together, we will advance evidence generation that improves outcomes for patients across Asia.

Message from the National Cancer Center Hospital Director

Launched in 2020, ATLAS marks its fifth anniversary this year. Over this period, we have steadily built a trusted clinical research network across Asia, strengthened the operational foundation for international studies, and expanded opportunities for training and collaboration among clinical research professionals.

These achievements have been possible only through the commitment of our partner institutions, investigators, research staff, and participating patients and families. I would like to express my sincere gratitude to all colleagues who have supported ATLAS and contributed to its progress.

In the coming years, we will further strengthen our collaborative framework, support the development of investigator initiated studies, and work to generate evidence that addresses clinical needs in Asia.



Yasuyuki Seto, MD. PhD.

National Cancer Center Hospital
Hospital Director


ATLAS's Three Key Purposes

The Asian Clinical Trials Network for Cancers Project (ATLAS Project) is an initiative led by the National Cancer Center Hospital to establish a regional clinical trial network for cancer across Asia. Launched in September 2020 with support from the Japan Agency for Medical Research and Development (AMED), ATLAS aims to accelerate international collaboration in the development of pharmaceuticals and medical devices.



Governance: Establishing a permanent international research group consisting of leading investigators from across Asia.

Our Partners



Clinical Research Malaysia
CRM, a Malaysian government-owned CRO, partners with ATLAS to facilitate multinational clinical trials and expand international research networks



Thai Society of Clinical Oncology
A Thai oncology society collaborating with ATLAS to strengthen joint research, academic exchanges, and clinical trial networks in Thailand.



European Organisation for Research and Treatment of Cancer (EORTC)
A European research organization collaborating with ATLAS as a coordinating center to manage and conduct clinical trials across Asian institutions



Japan Clinical Oncology Group (JCOG)
A Japanese cooperative oncology group partnering with ATLAS to support domestic multicenter clinical trials in Japan.

ATLAS by Numbers

as of December 2025



10

**countries and
regions**

42

institutions

420+

active members
Investigators
and research staff



5

**ongoing
clinical trials**



3

study groups
Head and Neck
Sarcoma and Rare Cancer
Hepatobiliary Pancreatic

2800+



**enrolled patients
in total**

2025 Performance

(Jan 2025–Dec 2025)



4 new clinical trials (under preparation)

ATLAS2501
STRAP trial
Head and
Neck
Cancer

ATLAS2502
PLATANUS
trial
Gastric
Cancer

ATLAS2503
XANTHOS
trial
Thymic
Cancer

ATLAS2504
ARTEMIS
trial
Head and
Neck Cancer



4

**peer-reviewed
articles**



16

**conference
presentations**



543

patients enrolled


Articles

1. Maruki Y, Yatabe Y, Mizoguchi C, et al. FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study. *Hepatol Res.* 2026;56:78–88.
2. Sim RHZ, Voon PJ, Cheo SW, et al. Novel Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Beyond EGFR and Checkpoint Blockade. *Biomedicines.* 2025;13(8):1972.
3. Sekiguchi M, Shinmura K, Sumiyama K, et al. Protocol for a multicenter randomized controlled trial to assess the usefulness of computer-aided detection systems for colonoscopy in colorectal cancer screening in the Asia-Pacific region (project CAD/NCCH2217). *Jpn J Clin Oncol.* 2025;55(7):837–840.
4. Tokura M, Ando MM, Kojima Y, et al. Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study. *Breast Cancer (Auckl).* 2024;18:1–13.

Conference Presentations


1. Ordinario MVC, et al. Genomic Landscape of Circulating Tumor DNA in Triple Negative Breast Cancer in Asia: NCCH1905/A-TRAIN study. 2026 JSMO Annual Meeting, Mar 2026. [Oral]
2. Nakamura K, et al. Multi-center Clinical Trials for Radiation Therapy in Japan. 2025 Annual Academic Conference on Oncology Radiotherapy, Nov 2025. [Oral]
3. Nakamura K, et al. Unlock your business potential in Japan - One-Stop Service Platform (OSSP) for Global Biotech. *ChinaTrials17*, Nov 2025. [Oral]
4. Nakamura K, et al. Forum dialogue: Investigator insight – New horizons in clinical development and quality. GCP renovation forum 2025, Nov 2025. [Oral]
5. Yang VS, et al. Soft Tissue Sarcoma Care Across Asia: A Multinational Survey of Physician Practice. CTOS 2025 Annual Meeting, Oct 2025. [Oral]
6. Tan DSP, et al. Analytical and clinical validation of a custom 18-gene targeted NGS panel for ctDNA in ovarian clear cell carcinoma: NCCH1905/A-TRAIN study. 2025 ESMO Congress, Oct 2025. [Poster]
7. Sekiguchi M, et al. Efficacy of computer-aided detection system on adenomatous and serrated lesion detection during colonoscopy (Project CAD). *UEG Week 2025*, Oct 2025. [Oral]
8. Nakamura K, et al. Fully decentralized clinical trials in oncology. 11st Intl Congress of Taiwan Assoc. of Gynecology, Sep 2025. [Oral]
9. Nakamura K, et al. Fully decentralized clinical trials in oncology. 2025 TMU Clinical Trials Insight, Sep 2025. [Oral]
10. Terada M, et al. Shaping Asia's Clinical Trial Landscape -Insights from the ATLAS Initiative. 3rd Malaysia - Japan Symposium on Pharm. Reg. System, Jul 2025. [Oral]
11. Nakamura K, et al. Unlocking Japan's Clinical Trial Landscape: Investigator's Perspective. 2025 DIA Global Annual Meeting, Jun 2025. [Oral]
12. Thinh NH, et al. Comprehensive profiling of ctDNA and microbial landscapes in nasopharyngeal cancer across Asia: NCCH1905/A-TRAIN study. 2025 ASCO Annual Meeting, May 2025. [Poster]
13. Nakamura K, et al. Japan's Experience in Conducting Multi-Regional Investigator-Initiated Trials. 2025 DIA China Annual Meeting, May 2025. [Oral]
14. Nakamura K, et al. Unlocking Japan's Clinical Trial Landscape: Investigator's Perspective. 2025 DIA China Annual Meeting, May 2025. [Oral]
15. Okuma H, et al. Overcoming Challenges in Rare Cancers: Leveraging Registry Data and Innovative Trial Designs. 46th Society for Clinical Trials, May 2025. [Oral]
16. Terada M, et al. Oncology Workshop. CRM trial connect 2025, May 2025. [Oral]

ATLAS-ARISE-PMDA International Symposium 2025



ATLAS 5-Year Symposium: Building a United Asian Clinical Trial Ecosystem

On 3 October 2025, the ATLAS 5-Year Symposium was successfully held at Hotel Okura Bangkok under the theme “Building a United Asian Clinical Trial Ecosystem”. This symposium was hosted by ATLAS in collaboration with ARISE and PMDA. The event brought together around 100 participants from across Asia



Establishment of ATLAS Hepatobiliary Pancreatic Cancer Group



Chair
Dr. Li-Tzong Chen
(Taiwan)



Secretary
Dr. Chigusa Morizane
(Japan)

ATLAS established the Hepatobiliary Pancreatic Cancer Group to advance collaborative research for hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer across Asia.

Dr Li-Tzong Chen of Taiwan serves as Chair, and Dr Chigusa Morizane of Japan serves as Secretary. Through regular discussion and capacity building, the group aims to generate evidence that addresses regional needs.

STRAP Trial (ATLAS2501): ATLAS Study Group Starts Preparations for Their Inaugural Interventional Trial



STRAP Trial (ATLAS2501) represents a milestone for ATLAS as we move from network building to delivering interventional research that can benefit patients across Asia. The trial concept was shaped through structured discussions within the ATLAS HNGC. STRAP trial illustrates how study group collaboration can translate shared needs into a concrete study plan. ATLAS will continue to support such pathways from concept to execution under rigorous ethical and scientific standards.

Oncology Workshop in CRM Connect 2025



The Oncology Workshop in CRM Connect 2025 was held in Kuala Lumpur for two days ahead of CRM Trials Connect. Clinical Research Malaysia (CRM) is a national organization that supports clinical research and hosts CRM Trials Connect, a regional forum for sharing best practices and building partnerships. Young investigators from outside Malaysia brought their own trial concepts. ATLAS Board members and National Cancer Center biostatisticians served as faculty. By pairing training with proposal development, ATLAS supports education and catalyzes new international trial ideas.

Clinical Research

- ATLAS Operational Model for Multinational IITs
- NCC Asian Partnerships Office, Bangkok
- PATHWAY
- MASTER KEY Asia
- CHOICE
- A-TRAIN
- HARMONY
- Project CAD

The names and designations used in this report are for descriptive and operational purposes only and do not imply any position on legal status, sovereignty, or diplomatic recognition.

ATLAS Operational Model for Multinational IITs

ATLAS has established a pragmatic and resource-efficient framework to deliver academia-led multinational clinical trials across Asia.

ATLAS Headquarters (NCCH, Japan) serves as the **Coordinating Sponsor**, providing centralized support for cross-border trial operations, including protocol development, data management, monitoring, and safety reporting.

At the country level, **Local Lead Sponsors** are responsible for regulatory submissions, ethics approvals, local safety reporting, and coordination with participating sites, enabling trial implementation within each jurisdiction.

Participating sites conduct patient enrollment and treatment, supporting site-level trial execution in collaboration with Local Lead Sponsors.

Pharmaceutical companies contribute investigational products and research funding, while **regulatory authorities** oversee trial conduct and play a key role in supporting future regulatory pathways for multinational development. **CROs** may be engaged as needed to complement operational capacity, depending on study requirements. Through this coordinated, academia-led model, ATLAS enables efficient and scalable multinational trials, supporting Asia's role in global clinical development.



NCC Asian Partnerships Office, Bangkok

11



Research Support for ATLAS Participating Sites

In collaboration with the NCCH ARO, ATLAS supports studies through monitoring, project management, and coordination of ATLAS Study Group activities.



Network Development

ATLAS expands its network through strategic communication and collaboration with key stakeholders across Asia.



Communications and Events

ATLAS organizes educational programs and events, while promoting its activities to external audiences through strategic communications.

Regional Hub for Clinical Trials in Asia

The ATLAS Team



Hitomi Okuma



Tomomi Hata



Mitsumi Terada



Chiharu Mizoguchi



Kathleen de Almeida



Celia St Clair



Chia Chen Li



Sameh Eltaybani



Tetsuya Sasaki



Tomozo Yamada



Takako Hitomi



Aya Miyata



Dat Nguyen-Tien



Thoopmanee
Kaendiao



Arthitada Hanada



Suchanya Leknoi



Takuya Sagara




Asuka Tsuzuki

Principal Investigator: Kan Yonemori (National Cancer Center Hospital, Japan)


Asian, international, multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial of tamoxifen with or without palbociclib +/- goserelin in women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. [NCCH1607/PATHWAY]

Key Achievements in 2025

- PATHWAY's first patient (enrolled in February 2018) completed overall survival follow-up on September 30, 2025.
- Results of the pharmacokinetic analysis, a secondary endpoint of the study, were presented at AACR 2025.



Study Schema



The NCCH1607/PATHWAY trial (NCT03423199) is an NCCJ-led international investigator-initiated study evaluating palbociclib in combination with tamoxifen for HR+/HER2- advanced or metastatic breast cancer. Conducted across 23 sites in Japan, South Korea, Taiwan, and Singapore, the study enrolled 184 patients spanning pre-, peri-, and postmenopausal populations. In collaboration with Pfizer Inc., which provided research funding and study drug supply, NCCJ served as the regulatory sponsor for participating Asian countries. The trial demonstrated significant PFS improvement and well tolerated safety profile. Based on the results of the PATHWAY trial, use of palbociclib in Japan has been expanded to include combination therapy with tamoxifen.

The primary analysis results for the trial were presented at ASCO 2023 and later published in *npj Breast Cancer*. Subsequent outputs include the translational research results presented at SABCS 2023 and the patient-reported outcomes presented at SABCS 2024. Pharmacokinetic findings were presented at AACR 2025, and manuscripts for all analyses are currently being either prepared or reviewed.

Progress Summary

ClinicalTrials.gov ID: NCT03423199

Sites: 23

Countries: 4

Total enrolled: 184

Status: Active/Not
recruiting

Principal Investigator: Noboru Yamamoto (National Cancer Center Hospital, Japan)

MASTER KEY Asia is an international collaborative prospective registry study focused on rare cancers, particularly in Asia. It aims to implement genomic medicine across the Asia-Pacific region, and build the largest rare cancer database worldwide, facilitating clinical development and genomic medicine through the aggregation of genomic information, treatment details, and prognoses of rare cancer patients.

Key Achievements in 2025

Major enrollment milestone

Reached the 1,000th patient enrollment, marking a significant milestone in the growth of one of Asia's largest rare cancer registries!

- **Launch of new disease-specific cohorts**
- **LMS cohort** launched in partnership with the Sarcoma Study Group
- **SIP + SNSCC cohort** launched in partnership with the Head and Neck Study Group

5th MASTER KEY Asia Investigators Meeting

Facilitating data sharing, progress reporting, and strategic planning among participating Asian institutions.

Advancement of genomic medicine in Asia

Continued accumulation of high-quality matched clinical, genomic, and outcome data, supporting exploratory translational research and the design of future biomarker-driven studies and trials!



Did you know? MASTER KEY Asia's mascot characters are male and female twins born on the island of Master Key. **Key**-chan is the active, strong-willed elder sister, while **Master**-kun is the quiet, thoughtful younger brother, and together they embark on an adventure to solve the mystery of cancer!



MKA countries!



Hitomi Okuma Chiharu Mizoguchi Kathleen de Almeida Chia Chen Li Thoopmanee Kaendiao Sarah Kruschwitz Wiwitkeyoonwong Jirapath Mitsumi Terada Tomomi Hata Aya Miyata Dat Nguyen-Tien Celia St Clair Sameh Eltaybani Kan Yonemori

This is our MKA team!

Progress Summary

ClinicalTrials.gov ID: NCT05217407

Sites: 29

Countries: 8

Total enrolled:
1004

Stage: Enrolling

Principal Investigator: Takuji Okusaka (National Cancer Center Hospital, Japan)

The CHOICE Study is a prospective clinical study to identify the clinical characteristics of patients with advanced cholangiocarcinoma who harbor the fibroblast growth factor receptor (FGFR) 2 rearrangement.

Key Achievements in 2025

- Peer-reviewed paper published, establishing the clinicogenomic foundation of the cohort.
- Ongoing translational and exploratory analyses leveraging integrated genomic and outcome data.
- Catalyst for collaboration, directly leading to the establishment of the Hepatobiliary & Pancreas Group (HBP Group) within the ATLAS framework!



CHOICE meeting and establishment of the HBP Study group, Singapore, December 2024.

ORIGINAL ARTICLE

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study

Yuta Maruki^{1,2} | Yumiko Yatabe¹ | Chiharu Mizoguchi¹ | Kaitsumi Yamashita¹ | Asumihiro Saito^{1,3} | Chikara Nakamura¹ | Ming-Hong Chen⁴ | Qingping Shao^{5,6} | Ting-Yan Ho⁷ | Shinya Inoue^{8,9} | Chayal Chantornwan¹⁰ | Hwan-Jin Lee¹¹ | Shinya Tanaka¹² | Shinya Yamaoka¹³ | Kanyaratni Kuntakornchai¹⁴ | Tansilak Sripornpanom¹⁵ | Hui-Jin Kim¹⁶ | Nigella Mui Kwan¹⁷ | Jodie Morrison¹⁸ | Silvana Santopinto Kusner¹⁹ | Kazuhiko Nakamura²⁰ | Chigusa Morikawa²¹ | Takuji Okusaka²²

¹Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan | ²Molecular Oncology, The First University Graduate School of Medicine, Tokyo, Japan | ³Department of Hepatobiliary Pathology, National Cancer Center Hospital, Tokyo, Japan | ⁴Department of International Clinical Oncology, National Cancer Center Hospital, Tokyo, Japan | ⁵Division of Medical Oncology, Shin-Kan University, Faculty of Medicine, Shin-Kan University, Thailand | ⁶Division of Medical Oncology, Faculty of Medicine, Shin-Kan University, Bangkok, Thailand | ⁷Department of Oncology, Singapore General Hospital, Singapore, Singapore | ⁸Division of Medical Oncology, Faculty of Medicine, Ramatubhai Hospital, Mahidol University, Bangkok, Thailand | ⁹Cancer Research and Clinical Trial Center, National Cancer Hospital, Osaka, Japan | ¹⁰Department of Clinical Oncology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia | ¹¹Department of Medical Oncology, Chong-Med University, Thailand | ¹²Department of Oncology, Radiotherapy and Palliative Care, Prince of Wales Hospital, George Town, Malaysia | ¹³Department of Radiotherapy & Oncology, National Cancer Institute, Jakarta, Indonesia | ¹⁴Department of Oncology, National Cancer University Hospital, Tokyo, Japan | ¹⁵Department of Radiotherapy, Hospital Sultan Ismail, Johor Bahru, Malaysia | ¹⁶Division of Medical Oncology, Prince of Songkla University Hospital, Songkhro, Thailand | ¹⁷Department of Radiotherapy, Oncology and Palliative Care, Hospital Universiti Sains Malaysia (General Hospital), Kelantan, Malaysia | ¹⁸Department of Radiotherapy and Oncology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia | ¹⁹Japan Clinical Oncology Group for Cancer Registration Office, National Cancer Center Hospital, Tokyo, Japan

Correspondence: Yuta Maruki (yuta.maruki@ncc.go.jp)

Received: 12 May 2023 | Revised: 1 August 2023 | Accepted: 27 August 2023



Handling Editor: Yuta Maruki

Keywords: Asia | FGFR2 | Fusions | Intrahepatic cholangiocarcinoma | Perihilar cholangiocarcinoma

ABSTRACT

Aims: Biliary tract cancers, including intrahepatic cholangiocarcinoma (ICC), are aggressive with limited treatment options and poor prognosis. Recent trials (STRONG, KAPLAN) have shown improved survival with 50% plus gemtuzumab and enfortumab. Targeted therapies, including FGFR inhibitors, are promising for cholangiocarcinoma patients with FGFR2 gene fusions or rearrangements, although few reports exist on FGFR2 positivity and clinical data in Asia. This study aims to address this gap by evaluating FGFR2 fusions or rearrangements in intrahepatic and perihilar cholangiocarcinoma patients across Asia, providing insights into their clinical significance and potential therapeutic implications.

Methods: This multicenter study evaluated the frequency of FGFR2 rearrangements and fusion genes in ICC and perihilar cholangiocarcinoma across Asia (Thailand, Malaysia, Vietnam, and Taiwan) using fluorescence in situ hybridization (FISH) and comprehensive genomic profiling with the TruSight Oncore² (TCO).



Maruki, Yuta et al. Hepatology Research, vol. 56,1 (2026): 78-88

Progress Summary

ClinicalTrials.gov ID: NCT05217407

Sites: 16	Countries: 4	Total enrolled: 113	Stage: Analysis
-----------	--------------	---------------------	-----------------


Principal Investigator: Kan Yonemori (National Cancer Center Hospital, Japan)

Asian multicenter prospective study of circulating tumor DNA sequencing [NCCH1905/A-TRAIN]

Key Achievements in 2025

- Across all cohorts, the data cleaning has been locked for a total of 386 cases.
- The analysis results from the cervical cancer, ovarian clear cell carcinoma, nasopharyngeal carcinoma, and ovarian cancer cohorts have been presented at international scientific conferences.
- Manuscripts for all cohorts are currently in preparation.

A-TRAIN (Study ID: NCCH1905, ClinicalTrials.gov Identifier: NCT05099978) is an international, multicenter, prospective study launched in 2021 under the ATLAS Project, which aims to establish an Asian clinical trial network. The study performs comprehensive analyses of circulating tumor DNA (ctDNA) in patients with metastatic and/or recurrent cancer across Asia. Participating regions include Japan, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. This study consists of 6 cohorts, and a collaboration agreement is established with a vendor for each cohort. We conducted ctDNA analysis focusing on cancers specific to Asia in collaboration with facilities across Asia. We are advancing our analysis with the goal of uncovering as many insights as possible for Asian cancer patients.



Progress Summary

ClinicalTrials.gov ID: NCT05099978

Sites: 20

Countries: 8

Total enrolled: 386


Stage: Analysis

Principal Investigator: Shin Takayama (National Cancer Center Hospital, Japan)



The HARMONY study:

- Assesses minimal residual disease (MRD) in HER2-positive early breast cancer across Asia.
- Evaluates post-treatment ctDNA detection and its association with cancer recurrence, generating genetic insights from liquid biopsies.



Key Achievements in 2025

■ Achieved the target patient enrollment of **60 participants**.

■ Published a peer-reviewed study:

✓ Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study

Breast Cancer: Basic and Clinical Research, 18, 1–13 (Tokura et al., 2024)

• Established a **prospective, multicenter MRD monitoring framework** using ctDNA in HER2-positive early breast cancer across Japan and the Philippines.

• Defined **standardized timepoints** for ctDNA assessment before and after NAC, surgery, and during follow-up.

• Aims to evaluate whether **post-treatment ctDNA (MRD) positivity is associated with recurrence (IDFS)** and can support future **risk-stratified treatment strategies**.



Shunichi Kudo



Shin Takayama



Marcelo Severino B. Imasa



Shinji Kohsaka



Mel Valerie Cruz-Ordinario



Yuki Kojima



Ayako Nakashoji



Maggie Chia Chien Li



Takako Hitomi



Kazumi Kurishita



Ayako Kumazawa

Progress Summary

ClinicalTrials.gov ID: NCT05433753

Sites: 2

Countries: 2

Total enrolled: 60

Stage: Follow-up

Principal Investigator: Yutaka Saito (National Cancer Center Hospital, Japan)

A multicenter randomized controlled trial to assess the usefulness of computer-aided detection systems for colonoscopy in colorectal cancer screening in the Asia-Pacific region.

Key Achievements in 2025


- Protocol paper published in Japanese Journal of Clinical Oncology.
- Planned recruitment target of 1400 participants by December 2025 achieved ahead of schedule in March 2025!
- Presentation of the study at United European Gastroenterology Week in Berlin, October 2025.



International recommendations regarding use of AI computer-aided detection systems in colonoscopy currently vary, and their adoption into routine practice is not yet widespread. As such, Project CAD aims to evaluate the efficacy of CADE-assisted colonoscopy in lesion detection compared with standard colonoscopy as part of routine colorectal cancer screening in the Asia-Pacific region.

We hope that the results of Project CAD can be used to inform guidelines internationally in this rapidly developing field, and improve the quality of CRC screening overall.

The trial recruited individuals undergoing routine colorectal cancer screening, either in the form of direct colonoscopy or colonoscopy after a positive fecal immunochemical test (FIT), were recruited to the study at 11 sites across Japan, South Korea, Taiwan, Singapore, Hong Kong, and Thailand.



Progress Summary

Trial ID: jRCT1032230396

Sites: 11

Countries: 6

Total enrolled:
1400

Stage: Analysis

ATLAS

Governance

- ATLAS Governance
- ATLAS Board
- Head and Neck Cancer Group
- Sarcoma and Rare Cancer Group
- Hepatobiliary and Pancreatic Cancer Group

The names and designations used in this report are for descriptive and operational purposes only and do not imply any position on legal status, sovereignty, or diplomatic recognition.

ATLAS Governance

ATLAS Board and Study Groups

Our objective is to build a sustainable framework that enables ATLAS to conduct high-quality clinical trials as an Asian multinational clinical trial group.

ATLAS governance is led by the ATLAS Board, which provides strategic oversight and prioritization. Disease-specific study groups generate research concepts and scientific direction, while ATLAS HQ, the operational office, and the NCC ARO support the operational management and implementation of studies across the network.


Why Study Groups?

- Clinical environments and disease characteristics differ across Asian countries –study designs must be disease-specific.
- Investigator networks are typically organized by organ/cancer type.
- Disease-focused expert groups enable trial-ready proposals from each country.

Impact of Study Groups on ATLAS

- Generates high-quality clinical trial concepts aligned with regional needs
- Drives multinational collaboration and consensus-building across Asia
- Expands the research network and strengthens study implementation capacity

ATLAS Governance Schema





President
Dr. Darren Wan-Teck Lim



President Elect
Dr. Tom Wei-Wu Chen



Former President
Dr. Kan Yonemori



Director, ATLAS HQ
Dr. Kenichi Nakamura

Country/Region	Name	
 National Principal Investigators		
Malaysia	Dr. Akhmal Yusof	Dr. Voon Pei Jye
Malaysia	Dr. Wan Zamaniah	
Philippines	Dr. Marcelo Severino Imasa	Dr. Jose Jasper Andal
Thailand	Dr. Ekaphop Sirachainan	Dr. Charuwan Akewanlop
Vietnam	Dr. Dao Van Tu	Dr. Dang Huy Quoc Thinh
Taiwan	Dr. Ming-huang Chen	Dr. Joelle Hui-Ching Wang
Korea	Dr. Jung-Yun Lee	Dr. Wonyoung Choi
Singapore	Dr. Yoon-Sim Yap	
Japan	Dr. Ken Kato	Dr. Hidehito Horinouchi
 Study group chair		
Singapore	Dr. Darren Wan-Teck Lim (HNCG)	
Taiwan	Dr. Tom Wei-Wu Chen (SRCG)	Dr. Li - Tzong Chen (HBPG)
 Top enrolling sites (PIs)		
Japan	Dr. Hitomi Okuma	
Thailand	Dr. Sukit Pattarajierapan	
Taiwan	Dr. Chi-Yang Chang	
Japan	Dr. Kazuki Sumiyama	
 Elected members		
Japan	Ms. Tomomi Hata	Dr. Kazuki Sudo
Japan	Dr. Mitsumi Terada	

Head and Neck Cancer Group



Chair
Dr. Darren Wan-Teck
Lim Singapore



Secretary
Dr. Pei Jye Voon
Malaysia

Key Achievements in 2025

- **Peer-reviewed publication**

Sim RHZ. Novel Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Beyond EGFR and Checkpoint Blockade.

Biomedicines, 2025.

- **First ATLAS interventional Phase II trial initiated (Singapore, Japan, Korea, Malaysia).**
- **Three additional international trials under development.**
- **HEADWAY real-world database framework.**
- **Asia-wide clinical practice survey initiated.**



Head and Neck Cancer Group

Established in February 2024, the Head and Neck Cancer Group (HNCG) is the first disease-specific study group within the ATLAS network, aiming to address the high burden of head and neck cancer in Asia through translational research, real-world evidence, and multi-country clinical trials.

Activities and Progress in 2025

In fiscal year (FY) 2025, the HNCG advanced its clinical research activities within the ATLAS network, with a focus on international investigator-initiated trials and data-driven research. A key milestone was the initiation of a Phase II international clinical trial for adenoid cystic carcinoma and papillary thyroid carcinoma. This study is the first ATLAS interventional trial using an investigational product, supported by an industry partner, and is led by the Group Chair, Dr. Darren Wan-Teck Lim, as Principal Investigator. Sites in Singapore, Japan, Korea, and Malaysia are participating, with patient enrollment planned for FY2026. In addition, three further international collaborative trials are under development with ongoing industry engagement. The group also advanced the HEADWAY project, a RedCap-based real-world data initiative for head and neck cancer. By FY2025, the data dictionary and protocol were largely finalized, with data collection expected to begin in FY2026. Academic activities included the publication of a review article on emerging therapeutic strategies in head and neck squamous cell carcinoma and the conduct of a region-wide survey of clinical practice in Asia.

No of Members

≥17

No of Countries
and regions

7

No of Research

8

*FY2025 (Apr. 2025 to Mar. 2026)

Sarcoma and Rare Cancer Group



Chair
Dr. Tom Wei-Wu Chen
Taiwan



Secretary
Dr. Hitomi Okuma
Japan

Key Achievements in 2025

- International collaboration with EORTC**

Participated in a meeting of the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group. This created a direct pathway for future joint work with established oncology group.



Group photo from the EORTC meeting

- Oral presentation accepted at the leading congress**

Our first Asia-wide survey work was accepted for presentation at the Connective Tissue Oncology Society Annual Meeting, strengthening external visibility and trust in the group's outputs.



Dr. Valerie Yang presenting at CTOS 2025

Sarcoma and Rare Cancer Group

Established in Aug 2024, ATLAS-SRCG is a disease-focused group within ATLAS to strengthen sarcoma/rare cancer evidence generation and trial readiness in Asia, leveraging multinational collaboration, surveys/RWD, and the MASTER KEY Asia platform toward future investigator-initiated interventional trials.

Activities and Progress in FY2025

- Working Group 1: Asia-wide physician survey on soft tissue sarcoma care**

(Lead: Dr. Valerie Shiwen Yang, OncoCare CancerCentre, Singapore)

- Working Group 2: MASTER KEY Asia, Leiomyosarcoma Project**

(Lead: Dr. Chiharu Mizoguchi, National Cancer Center Hospital, Japan; Co-lead: Dr. Tom Wei-Wu Chen, National Taiwan University Hospital, Taiwan) A international cohort study collecting standardized clinical information for leiomyosarcoma (a sarcoma arising from smooth muscle) through MASTER KEY Asia, a shared data platform for rare cancers.

- Working Group 3: Clinical trial concept for postoperative radiotherapy in localized myxofibrosarcoma**

(Lead: Dr. Shintaro Iwata, National Cancer Center Hospital, Japan)

- New proposals:** multiple additional study ideas were proposed (structured literature reviews, retrospective studies, and further surveys) to broaden participation and sustain the research projects.

No of Members

≥22

No of Countries
and regions


8

No of Research

8

*FY2025 (Apr. 2025 to Mar. 2026)

Hepatobiliary and Pancreatic Cancer Group



Chair
Dr. Li-Tzong Chen
Taiwan



Secretary
Dr. Chigusa Morizane
Japan

Key Achievements in 2025

- Planning of a Phase III neoadjuvant trial for HCC and an international collaborative trial for genetically defined BTC
- BANANA study: an international multicenter retrospective study
- Participation in quality-of-life questionnaire update projects led by the EORTC Quality of Life Group
- Successful organization of the first face-to-face group meeting in Singapore (December 2025)



Hepatobiliary and Pancreatic Cancer Group

Established in July 2025, the Hepatobiliary and Pancreatic Cancer Group (HBPg) is the third study group within the ATLAS network, focusing on hepatobiliary and pancreatic cancers with poor prognosis and limited effective treatment options across Asia. Despite its recent establishment, the group has rapidly proposed multiple interventional trial concepts. By bringing together a multidisciplinary community of medical oncologists, surgeons, and radiation oncologists, the HBPg aims to foster Asia-led collaboration and accelerate the development of multinational clinical studies for these high-unmet-need cancers.

Activities and Progress in FY2025

In FY2025, the HBPg initiated multiple research activities to establish an Asia-led clinical trial pipeline. Several interventional trial concepts are under development, including a Phase III intergroup study (JCOG, TCOG and ATLAS) of neoadjuvant therapy for hepatocellular carcinoma and an international collaborative trial (TCOG and ATLAS) evaluating a targeted agent in patients with genetically defined biliary tract cancer, with ongoing discussions with industry partners. The group also advanced the BANANA study, an international multicenter retrospective study covering hepatocellular carcinoma, biliary tract cancer, pancreatic cancer, and neuroendocrine neoplasms, with institutional review board submission completed at the National Cancer Center Japan. International collaboration progressed through participation in questionnaire update projects led by the EORTC Quality of Life Group for hepatocellular carcinoma (EORTC QLQ-HCC18) and biliary tract cancer (EORTC QLQ-BIL21), with patient enrollment planned for the coming fiscal year.

No of Members

≥42

No of Countries
and regions

10

No of Research

5

*FY2025 (Apr. 2025 to Mar. 2026)

Education

The names and designations used in this report are for descriptive and operational purposes only and do not imply any position on legal status, sovereignty, or diplomatic recognition.

ICRweb

e-Learning site about clinical research
Introduction to Clinical Research

ICRweb app is now available in English all over the world!

HOW TO DOWNLOAD

Please try searching for "ICRwebAppen" on the Apple Store or Google Play!

Available in English in selected regions, with more to come soon!
Website <https://www.icrweb.jp/my/index.php>

Introduction to Clinical Research web (ICRweb) is an e-learning site that provides knowledge required for clinical research, intended not only for medical researchers who conduct clinical research, but also for clinical research coordinators (CRC) and other clinical research professionals who support it, members and secretariat of the ethics review committee, and all those assist in the administrative work of research.

It is also intended for fundamental researchers, epidemiologists, statisticians, and the general public who wish to learn about clinical research.

Course List

Cancer Genomic Medicine: Essential Course

Overview of the main steps in the NGS workflow

Wet bench process

FFPE sample → Genomic DNA → NGS library → Read data

DNA extraction → Library preparation → Sequencing

Dry bench process

Alignment → Variant Calling → Annotation → Curation → Reporting

Reference: chr 17: 55319422 → 55321142 → 55321142 → 55321142 → 55321142

Read: ATTTTGGGTTT → TTTTGGGTTT → TTTTGGGTTT → TTTTGGGTTT → TTTTGGGTTT


Variant: G → T

Annotation: EGFR → L858R → T790M

Curation: Manual curation → Reporting


10 courses

Outline of Clinical Trials on Cancer



6 courses

Cancer Genomic Medicine: the Practice in Japan



8 courses

SICRES seminar

Educational seminar with SICRES on 5th July "THE IND JOURNEY FIRST-IN-HUMAN TRIAL"

The IND seminar

First in Human (FIH) trials

First in Human (FIH) trials

4 courses

Phase 1 Trial Development Course

Outline and Purpose of Phase I trial

- Outline
 - First administration of novel anticancer drugs in human (FIH: First-in-human)
 - Determining the optimal dose and administration method
 - Dose escalation test using toxicity as an index
- Purpose
 - Conducting safety assessment
 - Determining DLTs (dose-limiting toxicities)
 - Estimating MTD (maximum tolerated dose)
 - Determining RD (recommended dose) and administration method
 - Examining pharmacokinetic (PK) and pharmacodynamic (PD) markers
 - Determining administration method (such as schedule)
 - Examining biomarkers
 - Evaluating therapeutic effects (preliminary anti-tumor activity)

4 courses

Biostatistics for Clinical Trials on Cancer

3. Note on Calculating the p-value: One-Sided and Two-Sided p-values

- One-sided p-value = 35/1,000 = 0.035
Alternative hypothesis "RT < CRT"
- Two-sided p-value = 70/1,000 = 0.07
Alternative hypothesis "RT ≠ CRT"

Observed survival curves

RT is better

CRT is better

8 courses

CRC Training Course

Main duties of CRC in Cancer Clinical Trials

- Fully understanding of complex protocol
- Ability to manage the trial to ensure that it is properly conducted in accordance with the protocol
- Source data record and storage (SDR/SDC)
- Collecting and monitoring the latest safety information
- Knowledge of adverse events and proper evaluation of efficacy (CTCAE/RECIST)
- Prompt and appropriate response for SAEs
- Psychological support for the patient and patient's family
- Communication skills with end-of-life patients
- Cooperation with other medical professions
- Cooperation with the study sponsor

10 courses

ATLAS Monthly Webinar


ATLAS

ATLAS MONTHLY WEBINAR

27 courses

How to sign up

We have a total of 107 courses, including the following and other courses!




ATLAS Monthly Webinars

This is a seminar series focused on sharing the latest topics in comprehensive cancer knowledge, targeting physicians, researchers, and clinical trial professionals. The series covers a wide range of topics, from basic research to treatment and clinical trial.

[ATLAS Monthly Webinar | ATLAS Asia Clinical Trials Network for Cancers Project](https://atlas.ncc.go.jp/en/about/ATLAS-Monthly-Webinar/)
<https://atlas.ncc.go.jp/en/about/ATLAS-Monthly-Webinar/>



Participants' organizations




Distribution of academic participants across countries



*Countries with fewer than 20 members are omitted.

Distribution of industry participants across countries



*Countries with less than five members are omitted.

ATLAS Monthly Webinars

27

Date	Topic	Facilitator & Speakers
July 31st, 2024	Head and Neck Cancer	Dr. Darren Lim Wan Teck (National Cancer Centre Singapore, Singapore), Dr. ANG Mei-Kim (National Cancer Centre Singapore, Singapore), Dr. Wan Zamaniah Wan Ishak (University of Malaya Clinical Oncology, Malaysia)
August 26th, 2024	Lung Cancer	Dr. Hidehito Horinouchi (National Cancer Center, Japan), Dr. Kim Yeon Wook (Seoul National University Bundang Hospital, South Korea)
October 14th, 2024	Malignancy in People Living with HIV	Dr. Jose Jasper Andal (St. Luke's Medical Center, Philippines), Dr. Marcelo Severino B. Imasa (St. Luke's Medical Center, Philippines), Dr. Jay Ty Datukan (St. Luke's Medical Center, Philippines), Dr. Gelza Mae A. Zabat (St. Luke's Medical Center, Philippines)
November 26th, 2024	Melanoma	Dr. Wonyoung Choi (National Cancer Center, Korea), Dr. Sang Joon Shin (Yonsei Cancer Center, South Korea), Dr. Nguyen Hoang-Quy (Ho Chi Minh City Oncology Hospital, Vietnam)
December 26th, 2024	Radiation Oncology	Dr. Pittaya Dankulchai (Siriraj Hospital, Thailand), Dr. Keiji Nihei (Kansai BNCT Medical Center, Japan), Dr. Charuwan Akewanlop (Siriraj Hospital, Thailand), Dr. Wajana Thaweerat (Siriraj Hospital, Thailand), Dr. Satoshi Takeno (Kansai BNCT Medical Center, Japan)
January 27th, 2025	Endoscopy	Dr. Masau Sekiguchi (National Cancer Center, Japan), Dr. Wenfeng Hsu (National Taiwan Hospital, Taiwan)
February 24th, 2025	Cervical Cancer	Dr. Voon Pei Jye (Sarawak General Hospital, Malaysia), Dr. Izzati Wan Maharuddin (Sarawak General Hospital, Malaysia), Dr. Suwanit Therasakvichya (Siriraj Hospital, Thailand)
March 27th, 2025	Sarcoma	Dr. Tom Wei-Wu Chen (National Taiwan University Hospital, Taiwan), Dr. Valerie Yang (National Cancer Centre Singapore), Dr. Jen-Chieh Lee (National Taiwan University Hospital, Taiwan)
April 24th, 2025	Collaboration in cancer research across different Asian countries	Dr. Yap Yoon-Sim (National Cancer Centre Singapore, Singapore), Dr. David SP Tan (National University Cancer Institute Singapore, Singapore), Dr. Kan Yonemori (National Cancer Center, Japan)
May 29th, 2025	Academia-Regulatory Collaboration for Asian Therapeutic Development	Dr. Yuta Sekino (National Cancer Center, Japan), Dr. Jun Kitahara (Pharmaceuticals and Medical Devices Agency, Japan), Dr. Mitsumi Terada (National Cancer Center, Japan)
July 30th, 2025	Locally Advanced Rectal Cancer	Dr. Ekaphop Sirachainan (Ramathibodi Hospital, Thailand), Dr. Keeratikarn Boonyawan (Bumrungrad International Hospital, Thailand), Dr. Yasuyuki Takamizawa (National Cancer Center, Japan)
August 27th, 2025	Liquid Biopsy and Emerging Biomarkers	Dr. Jose Jasper Andal (St. Luke's Medical Center, Philippines), Dr. Takahiro Kogawa (Japanese Foundation for Cancer Research, Japan), Dr. Edward Chow (Kyan Technologies, USA), Dr. Pashtoon Kasi (City of Hope, USA)
September 30th, 2025	Cancer Registration and Epidemiology in Asia	Dr. Tomohiro Matsuda (National Cancer Center, Japan), Dr. Siti Norbayah binti Yusof, National Cancer Institute, Malaysia), Dr. Nguyen Huong Giang (Vietnam National Cancer Institute, Vietnam)
November 17th, 2025	Perioperative Immune Therapy in Gastric Cancer	Dr. Ming-huang Chen (Taipei Veterans General Hospital, Taiwan), Dr. Chau Hsien Matthew (National Cancer Centre Singapore, Singapore), Dr. Sun Yung Rha (Yonsei University, South Korea)
December 23th, 2025	Particle Radiation Therapy	Dr. Yuta Sekino (National Cancer Center, Japan), Dr. Tairo kashihara (National Cancer Center, Japan), Dr. Hsiang-Kuang Tony Liang (National Taiwan University, Taiwan)

ATLAS Capacity Building Program

FY 2025 physician course



FY 2025 CRC course



FY 2025 ISO course



The ATLAS Capacity Building Program is an educational initiative under the ATLAS Project. We organize three courses for Clinical Research Coordinators (CRCs), physicians, and ISO 15189. Participants in this program come from around the world, particularly from Thailand, Vietnam, Taiwan, and Malaysia.

The program offers unique learning opportunities, including lectures on Phase I oncology clinical trials and roundtable discussions with members of the ATLAS team. The CRC and physician courses also include a tour of a Phase I clinical trial unit at another hospital in Tokyo.

The ISO course features lectures on cancer genomic profiling tests and risk management delivered by Professor Miyachi, Dean of Nitobe Bunka College, as well as visits to related facilities and the SRL Central Laboratory in Akiruno City, where participants learn about clinical trial operations.

The ATLAS Capacity Building Program enabled the ATLAS team to engage with physicians and CRCs worldwide and strengthen international collaboration.

FY 2025 participants list

FY	Course	Country	Sites
FY2025	Physician	Vietnam	Ho Chi Minh City Oncology Hospital
FY2025	Physician	Thailand	Khon Kaen University
FY2025	CRC	Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital
FY2025	CRC	Malaysia	Clinical Research Malaysia (CRM)/ Hospital Pulau Pinang
FY2025	ISO	Thailand	Natioal Cancer Institute, Thailand
FY2025	ISO	Vietam	Ho Chi Minh City Oncology Hospital

Total number of participants

FY	Physician	CRC	ISO	Total
FY2023	4	3	4	11
FY2024	2	2	4	8
FY2025	2	2	2	6
Total	8	7	10	25

*FY2025 (Apr. 2025 to Mar. 2026)

Activity Report

The names and designations used in this report are for descriptive and operational purposes only and do not imply any position on legal status, sovereignty, or diplomatic recognition.

ATLAS Activity Report

We are pleased to report ATLAS Project activities over the past year. For further details, please visit the ATLAS Project's official social media channels.

Date	Category	Activity
3 Apr 2025	Event	Japan-Taiwan Joint Workshop - Biotechnology Innovation and Biomedical Treatment Workshop was held.
14 Apr 2025	Event	Dr. Yatabe visited Thailand to meet with doctors from the Siriraj Hospital and Ramathibodi Hospital.
21 Apr 2025	Clinical Trial	Members of the ATLAS Sarcoma and Rare Cancer Group had an online meeting.
24 Apr 2025	Event	The 9th ATLAS Monthly Webinar (Collaboration in cancer research across different Asian countries) was held.
6 May 2025	Event	Report: Oncology Workshop Day 1 - CRM Trial Connect 2025
6 May 2025	Event	ATLAS Collaborative Sessions were held at the CRM Trial Connect 2025.
7 Jun 2025	Event	Report: Oncology Workshop Day2 - CRM Trial Connect 2025
9 May 2025	Event	Report: ATLAS & ARISE Track - CRM Trial Connect 2025
20 May 2025	Event	ATLAS Project team visited Health Systems Research Institute (HSRI).
21 May 2025	Clinical Trial	Dr. Nakamura, Dr. Okuma, Dr. Mizoguchi and Dr. Mizusawa presented at the 46th Annual Meeting of the Society for Clinical Trials in Canada, an invited session titled "Overcoming challenges in rare cancers: Leveraging registry data and innovative trial designs".
28 May 2025	Event	ATLAS Project team visited King Chulalongkorn Memorial Hospital.
30 May 2025	Event	The 10th ATLAS Monthly Webinar (Academia-Regulatory Collaboration for Asian) was held.
2 Jun 2025	Clinical Trial	The A-TRAIN Study's 03 cohort (Nasopharyngeal Cancer cohort) was presented as a poster at ASCO 2025.
5 Jun 2025	Clinical Trial	MASTERKEY Asia – 4th Investigators Meeting was held.
9 Jun 2025	Event	JICA-ACPHEED (ASEAN Centre for Public Health Emergencies and Emerging Diseases) visited the Asian Partnerships Office in Bangkok.
10 Jun 2025	Event	Mr. Takuya Sagara from the Asian Partnerships Section worked at the APO in Thailand for a one-month assignment to enhance his professional skills.
23 Jun 2025	Event	Mr. Watanabe from The Chemical Daily Co., Ltd. Visited Asian Partnerships Office in Bangkok and interviewed the ATLAS Project team.

ATLAS Activity Report

Date	Category	Activity
23 Jun 2025	Clinical Trial	ATLAS Semi-Annual Meeting was held.
23 Jun 2025	Event	The ATLAS Project supported a delegation from the Division of Radiation Oncology at Siriraj Hospital, Thailand, in their visit to radiation therapy facilities in Japan.
27 Jun 2025	Event	A discussion with the JPMA Drug Evaluation Committee / International Affairs Committee (Asia Committee), the Japan Institute for Health Security (JIHS), and the Pharmaceuticals and Medical Devices Agency (PMDA) Asia Office.
16 Jul 2025	Event	Prof. Yoshihiko Takubo from the GLOBIS University, to the National Cancer Center for a special lecture: “Driving Organizational Change – Action Strategies for Those Who Won’t Give Up.”
18 Jul 2025	Event	Dr. Harumasa Nakamura from the National Center of Neurology and Psychiatry visited the Asian Partnerships Office in Bangkok.
24 Jul 2025	Event	Dr. Yi-Jen Chen from Taipei Veterans General Hospital (TVGH) visited the National Cancer Center Hospital to discuss the MASTER KEY Asia project.
29 Jul 2025	Event	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - University Malaya Medical Centre (UMMC).
29 Jul 2025	Event	The 11th ATLAS Monthly Webinar (Locally Advanced Rectal Cancer) was held.
30 Jul 2025	Event	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - Institut Kanser Negara (National Cancer Institute).
30 Jul 2025	Event	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - Hospital Kuala Lumpur (HKL).
31 Jul 2025	Event	Dr. Terada presented at the 3rd Malaysia-Japan Symposium on Pharmaceutical Regulatory System.
27 Aug 2025	Event	The 12th ATLAS Monthly Webinar (Liquid Biopsy and Emerging Biomarkers) was held.
5 Sept 2025	Event	Mr. Toru Kajiwara, Minister, and Mr. Yosuke Kobayashi, First Secretary, from the Embassy of Japan in Thailand visited the Asian Partnerships Office in Bangkok.
11 Sept 2025	Event	Kazuhiro Miyazaki, CEO of TwinCapsula Inc., visited the Asian Partnerships Office in Bangkok.
30 Sept 2025	Event	The 13th ATLAS Monthly Webinar (Cancer Registration and Epidemiology in Asia) was held.
2 Oct 2025	Event	Dr. Sekino visited the Siriraj Institute of Clinical Research (SICRES) with Dr. Akhmal Yusof, CEO of Clinical Research Malaysia (CRM).
3 Oct 2025	Event	The ATLAS-ARISE-PMDA Symposium was held in Bangkok, Thailand.

ATLAS Activity Report

Date	Category	Activity
9 Oct 2025	Clinical Trial	The ATLAS Sarcoma and Rare Cancer Group (ATLAS SRCG) joined the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meeting.
17 Oct 2025	Clinical Trial	A poster presentation on the Ovarian Clear Cell Carcinoma (OCCC), cohort of the A-TRAIN study, was given at ESMO 2025.
22 Oct 2025	Event	Dr. Kota Katanoda, Division Chief of the Division of Population Data Science, Institute for Cancer Control, National Cancer Center Japan visited the Asian Partnerships Office in Bangkok.
23 Oct 2025	Clinical Trial	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - Hospital Sultan Ismail Johor Bahru (HSIJB).
24 Oct 2025	Clinical Trial	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - Hospital Umum Sarawak.
28 Oct 2025	Clinical Trial	Dr. Sekino conducted an audit visit to our collaborating partners in Malaysia. - Hospital Pulau Pinang.
30 Oct 2025	Clinical Trial	The ATLAS Sarcoma and Rare Cancer Group held its regular meeting.
30 Oct 2025	Clinical Trial	The results of the CHOICE Study have been published.
11 Nov 2025	Clinical Trial	The ATLAS Head and Neck Cancer Group Meeting was held at Regent Taipei, Taiwan.
14 Nov 2025	Clinical Trial	Members from the ATLAS Sarcoma and Rare Cancer Group (ATLAS SRCG) joined the 30th Connective Tissue Oncology Society Annual Meeting (CTOS 2025).
3 Dec 2025	Event	The ATLAS Project Team visited Tan Tock Seng Hospital (TTSH) and the Singapore Translational Cancer Consortium (STCC) in Singapore.
4 Dec 2025	Clinical Trial	The ATLAS Project Team conducted on-site monitoring for the Master Key Asia at the National Cancer Centre Singapore (NCCS).
5 Dec 2025	Clinical Trial	The first in-person meeting of the ATLAS HBPG (Hepatobiliary and Pancreatic Cancer Group) was held in Singapore.
5 Dec 2025	Clinical Trial	The ATLAS Board meeting was held in Singapore.
5 Dec 2025	Event	The ATLAS project session was held at ESMO Asia.
18 Dec 2025	Clinical Trial	The ATLAS Semi-Annual Meeting was held.
19 Dec 2025	Event	Dr. Sekino was Invited to Bangkok Hospital ceremony.
23 Dec 2025	Event	NCC staff from the Institute for Cancer Control, NCCJ visited the Asian Partnerships Office in Bangkok.
23 Dec 2025	Event	The 15th ATLAS Monthly Webinar (Particle Radiation Therapy) was held.



facebook.com/NCCH.ATLAS.project/



x.com/ATLAS_by_NCC



linkedin.com/company/atlas-project-by-national-cancer-center-japan/



<https://atlas.ncc.go.jp/en/>